Literature DB >> 12390966

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.

Tjalf Ziemssen1, Tania Kümpfel, Wolfgang E F Klinkert, Oliver Neuhaus, Reinhard Hohlfeld.   

Abstract

The clinical effects of glatiramer acetate (GA), an approved therapy for multiple sclerosis, are thought to be largely mediated by a T-helper 1 (TH1) to T-helper 2 (TH2) shift of GA-reactive T-lymphocytes. Current theories propose that activated GA-reactive TH2 cells penetrate the CNS, release anti-inflammatory cytokines such as interleukin (IL)-4, IL-5 and IL-10, and thus inhibit neighbouring inflammatory cells by a mechanism termed 'bystander suppression'. We demonstrate that both GA-specific TH2 and TH1 cells produce the neurotrophin brain-derived neurotrophic factor (BDNF). As the signal-transducing receptor for BDNF, the full-length 145 tyrosine kinase receptor (trk) B, is expressed in multiple sclerosis lesions, it is likely that the BDNF secreted by GA-reactive TH2 and TH1 has neurotrophic effects in the multiple sclerosis target tissue. This may be an additional mechanism of action of GA, and may be relevant for therapies with altered peptide ligands in general. To demonstrate that GA-reactive T cells produce BDNF, we selected four GA-specific, long-term T-cell lines (TCLs), which were characterized according to their cytokine profile by intracellular double-fluorescence flow cytometry. Three TCLs (isolated from a normal subject) had the phenotypes TH1, TH1/TH0, and TH0; the fourth, derived from a GA-treated patient, had the phenotype TH2. To demonstrate BDNF production, we used a combination of RT-PCR (reverse transcription-polymerase chain reaction) and two specially designed techniques for BDNF protein detection: one was based on ELISA (enzyme-linked immunosorbent assay) of supernatants from co-cultures of GA-specific TCLs plus GA-pulsed antigen-presenting cells, and the other on the direct intracellular staining of BDNF in individual T cells and flow cytometric analysis. The different assays and different TCLs yielded similar, consistent results. All four GA-specific T-cell lines, representing the major different TH phenotypes, could be stimulated to produce BDNF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390966     DOI: 10.1093/brain/awf252

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  58 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 2.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 3.  Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

Review 4.  Combination therapy in multiple sclerosis.

Authors:  Mark J Tullman; Fred D Lublin
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

5.  Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3.

Authors:  Jian Hong; Ningli Li; Xuejun Zhang; Biao Zheng; Jingwu Z Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-25       Impact factor: 11.205

6.  Immune agents for the treatment of Devic's neuromyelitis optica.

Authors:  R Bergamaschi
Journal:  Neurol Sci       Date:  2007-10       Impact factor: 3.307

7.  Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity.

Authors:  Refik Pul; Darius Moharregh-Khiabani; Jelena Škuljec; Thomas Skripuletz; Niklas Garde; Elke Verena Voss; Martin Stangel
Journal:  J Neuroimmune Pharmacol       Date:  2010-11-03       Impact factor: 4.147

Review 8.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

9.  Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis.

Authors:  Yael Barhum; Sharon Gai-Castro; Merav Bahat-Stromza; Ran Barzilay; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2009-11-10       Impact factor: 3.444

10.  Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected] integrin.

Authors:  Avik Roy; Xiaojuan Liu; Kalipada Pahan
Journal:  J Biol Chem       Date:  2007-09-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.